| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Research Abstract |
Impaired regulation of immunity in the gut is implicated in the pathogenesis of inflammatory bowel disease (IBD). Regulatory T cells (Treg) possess immnoregulatory activity and are a possible tool for the treatment of IBD. Recent studies suggest that T helper (Th) 1 and Th17 responses are augmented in the gut of IBD. Treg are capable of suppressing Th1-mediated colitis. However, it has not been clarified whether Th17-mediated colitis can be suppressed by Treg. In this study, we demonstrated that Treg are capable of suppressing Th17-mediated colonic inflammation as well as Th1-mediated colitis. It is therefore reasonable to consider utilization of Treg for the IBD treatment even if Th17 is involved in its pathogenesis.
|
